Payment overview · 2025
General Payments
$850.85
37 reported records · 21 companies
Healthcare provider profile · identity verified
Thomas Joseph Miller, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLAXTON, GA · NPI 1407173347
Verified facts
What the public records show
CMS Open Payments records show Thomas Joseph Miller, M.D. received $850.85 in general payments during 2025 across 37 reported records.
Axsome Therapeutics, Inc. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $176.60 | 20.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.28 | 10.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.01 | 8.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.74 | 7.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.21 | 7.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $50.52 | 5.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.97 | 5.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.67 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.80 | 3.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.93 | 2.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.35 | 2.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.10 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.91 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.65 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.69 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.68 | 2.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.05 | 2.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.41 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.29 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.11 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.88 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $850.85 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $176.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.01 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.01 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.74 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.21 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.63 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.63 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.63 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 224 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 375 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 109 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
103 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
375 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
109 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
224 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 849 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 838 | 214 |
| Omeprazole | Omeprazole | 772 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 708 | 152 |
| Lisinopril | Lisinopril | 636 | 158 |
| Gabapentin | Gabapentin | 589 | 143 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 514 | 83 |
| Losartan Potassium | Losartan Potassium | 497 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 449 | 122 |
| Simvastatin | Simvastatin | 425 | 108 |
| Furosemide | Furosemide | 388 | 121 |
| Potassium Chloride | Potassium Chloride | 387 | 108 |
| Ozempic | Semaglutide | 375 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 345 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 87 |
| Trazodone Hcl | Trazodone Hcl | 292 | 75 |
| Metformin Hcl | Metformin Hcl | 284 | 71 |
| Carvedilol | Carvedilol | 282 | 82 |
| Famotidine | Famotidine | 271 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 270 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 263 | 99 |
| Fluticasone Propionate | Fluticasone Propionate | 261 | 106 |
| Meloxicam | Meloxicam | 244 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 61 |
| Eliquis | Apixaban | 224 | 53 |
| Lorazepam | Lorazepam | 222 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 218 | 55 |
| Sertraline Hcl | Sertraline Hcl | 210 | 49 |
| Buspirone Hcl | Buspirone Hcl | 209 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 201 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 188 | 37 |
| Atenolol | Atenolol | 182 | 42 |
| Glimepiride | Glimepiride | 178 | 52 |
| Allopurinol | Allopurinol | 177 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 41 |
| Montelukast Sodium | Montelukast Sodium | 155 | 36 |
| Azithromycin | Azithromycin | 152 | 133 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 43 |
| Jardiance | Empagliflozin | 145 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 36 |
| Donepezil Hcl | Donepezil Hcl | 139 | 33 |
| Xarelto | Rivaroxaban | 128 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 126 | 87 |
| Alprazolam | Alprazolam | 125 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 120 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 29 |
| Tramadol Hcl | Tramadol Hcl | 119 | 34 |
| Dexamethasone | Dexamethasone | 115 | 92 |
| Ezetimibe | Ezetimibe | 114 | 34 |
| Chlorthalidone | Chlorthalidone | 111 | 34 |
| Rybelsus | Semaglutide | 109 | 23 |
| Meclizine Hcl | Meclizine Hcl | 108 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 87 |
| Colchicine | Colchicine | 107 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 22 |
| Myrbetriq | Mirabegron | 106 | 21 |
| Linzess | Linaclotide | 103 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 12 |
| Alendronate Sodium | Alendronate Sodium | 96 | 20 |
| Januvia | Sitagliptin Phosphate | 96 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 45 |
| Spironolactone | Spironolactone | 87 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 56 |
| Glipizide | Glipizide | 85 | 23 |
| Clonazepam | Clonazepam | 84 | 16 |
| Celecoxib | Celecoxib | 83 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 18 |
| Memantine Hcl | Memantine Hcl | 80 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 78 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 15 |
| Fenofibrate | Fenofibrate | 76 | 18 |
| Baclofen | Baclofen | 75 | 16 |
| Fluconazole | Fluconazole | 75 | 48 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 49 |
| Ibuprofen | Ibuprofen | 72 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 19 |
| Sucralfate | Sucralfate | 72 | 32 |
| Finasteride | Finasteride | 70 | 16 |
| Benazepril Hcl | Benazepril Hcl | 68 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 67 | 18 |
| Valsartan | Valsartan | 65 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 19 |
| Synthroid | Levothyroxine Sodium | 64 | 12 |
| Cefdinir | Cefdinir | 63 | 60 |
| Nystatin | Nystatin | 63 | 40 |
| Tradjenta | Linagliptin | 63 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 12 |
| Pregabalin | Pregabalin | 59 | 17 |
| Methylprednisolone | Methylprednisolone | 58 | 49 |
| Promethazine Hcl | Promethazine Hcl | 57 | 20 |
| Prednisone | Prednisone | 56 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 20 |
| Ondansetron Odt | Ondansetron | 55 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 46 |
| Estradiol | Estradiol | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 15 |
| Temazepam | Temazepam | 52 | suppressed |
| Aripiprazole | Aripiprazole | 51 | 14 |
| Primidone | Primidone | 50 | suppressed |
| Topiramate | Topiramate | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Levofloxacin | Levofloxacin | 46 | 39 |
| Mupirocin | Mupirocin | 45 | 38 |
| Fosinopril Sodium | Fosinopril Sodium | 44 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 18 |
| Amoxicillin | Amoxicillin | 43 | 40 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Cephalexin | Cephalexin | 42 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 13 |
| Glyxambi | Empagliflozin/Linagliptin | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 30 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 12 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | 11 |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | 11 |
| Acyclovir | Acyclovir | 29 | 11 |
| Clotrimazole | Clotrimazole | 29 | 22 |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 22 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Carbinoxamine Maleate | Carbinoxamine Maleate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $850.85 · 37 records | Axsome Therapeutics, Inc. | ABRYSVO, AIRSUPRA, AJOVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, IBSRELA, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TONMYA, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, WATCHMAN FLX, XIFAXAN, XYOSTED, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error